<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1538973079464292&amp;ev=PageView&amp;noscript=1">

Blog Subscribe

Facebook Twitter LinkedIn Copy to Clipboard

After having been selected for phase 2 in February, GLA- funded investigator Dr. Brandon Jutras and his lab are one of the six talented groups advancing to Phase 3 of the LymeX Diagnostics Prize. Dr. Jutras’ team is developing a test to identify a unique biomarker of the Lyme disease bacteria in blood and urine samples. This test combines advanced techniques, immuno-PCR and lateral flow technology, to give fast and accurate results. This innovative approach could revolutionize how we diagnose Lyme disease.

Next up, Dr. Jutras and his team will prepare to showcase their pioneering solutions at Demo Day in Fall 2024. With up to $2.1 million in prizes available in this phase, and further funding in Phase 4, the stakes are high and the potential for impact is huge.

What is LymeX

The LymeX Diagnostic Prize is a multiphase prize competition seeking to accelerate accurate diagnosis of an active infection of Lyme disease. The competition is helping teams overcome diagnostic development barriers by providing virtual learning, mentorship, biorepository subject matter expertise, and networking opportunities to move diagnostic tests from the laboratory through to the FDA for review.

We are proud to have supported Dr. Jutras from the beginning and are hopeful that this competition will help make Dr. Jutras’ long-term goal of developing an at-home urine test for Lyme disease a reality.   


Subscribe to newsletter